YDES Valuation — YD Bio Ltd

Biotechnology · Institutional-depth multi-model valuation on Equity Rank

As of October 22, 2026, YD Bio Ltd (YDES) trades at $4.40. No model fair value is published for YDES. Equity Rank publishes a blended model fair value only when enough valuation methods have usable data and pass its reliability checks. For YDES they currently do not (common causes are losses or negative cash flow, too little reporting history, or methods that disagree too widely), so no fair value is shown.

Source: Equity Rank — YDES valuation (data as of 2026-10-22). The full page shows the company’s fundamental profile and earnings data.

Current Price
$4.40
Model Fair Value
Not published
Margin of Safety
Not published

How YDES's valuation models agree

Equity Rank computed model fair value for YDES from 1 independent valuation methods with sufficient data. 1 place fair value above the current price of $4.40, and 0 place it below. No blended model fair value is published for this company. The larger group corresponds to potential undervaluation versus the current price.

Models: FV above price
1
Models: FV below price
0
Models compared
1

Each method (DCF, Graham Number, EPV, Three-Stage DCF, DDM, Residual Income, Justified Price-to-Book, and more) is weighted by historical sector accuracy. Model-derived and informational only — not investment advice.

YDES fundamental profile

Equity Rank's fundamental strength composite scores YDES at 34.7/100 (D+, Mixed), blending profitability, balance-sheet, and cash-flow quality. Its SAVE composite score has moved -5.6 over the past 30 days.

A composite quality metric for research context — not a rating, recommendation, or directional signal.

Why is there no fair value for YDES?

Equity Rank publishes a blended model fair value only when enough valuation methods have usable data and pass its reliability checks. For YDES they currently do not (common causes are losses or negative cash flow, too little reporting history, or methods that disagree too widely), so no fair value is shown. Informational only — not investment advice.

About YDES

YD Bio Ltd (YDES) is analyzed on Equity Rank with multiple valuation methods (DCF, Graham Number, multiples) and a Fundamentals Score built from value, growth, quality and financial stability. Where the data supports one, Equity Rank publishes a multi-method consensus fair value; none is published for this company at present.

YD Bio Ltd (YDES) is classified in the Biotechnology sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.

Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.

Related Biotechnology Research

JNJ · UNH · PFE · ABBV · MRK

All Biotechnology stocks with model fair values

All Healthcare stocks with model fair values · Undervalued Healthcare stocks

Research Tools

Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator

Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks

How to quote this page

Attribute figures to Equity Rank and link https://www.equity-rank.com/stocks/YDES. Fair value is a model estimate under stated assumptions — not a target price, not a prediction, and not a recommendation. Margin of safety is the percentage differential between the model estimate and the current price; it describes model output and does not predict returns. Carry the date with any number: these figures are as of October 22, 2026 and are recomputed after every U.S. market close.